Bronchodilators Market Overview
Bronchodilators Market Size was valued at USD 33.81 Billion in 2023. The Global Bronchodilators industry is projected to grow from USD 35.57 Billion in 2024 to USD 53.44 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.78% during the forecast period (2024 - 2032).
There has been a rise in the prevalence of COPD and asthma and a high level of technological improvement in bronchodilators in the past few years, which is fueling the global market growth. Also, as bronchodilators are used rigorously for all respiratory disorders, companies are investing in this market.

Market Drivers
Increase in prevalence of pulmonary disorders Growing technological advancements. The rise in disposable income. Increasing geriatric population Growing government initiatives for creating awareness among the general population. Increasing mergers and acquisitions by prominent players in the market. For instance, in April 2019, Cipla Technologies entered into an agreement with Pulmatrix Inc. to co-develop a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. Growing funding by government organizations
Market Restraints
- Side effects associated with bronchodilators
- Government regulations related to the safety & efficacy of the bronchodilators
Bronchodilators Market Segment Insights
Bronchodilators Drug Type Insights
Bronchodilators Disease Insights
-
COPD: Bronchodilators are the primary treatment for chronic obstructive pulmonary disease (COPD) as they help to alleviate bronchial obstruction and airflow limitation, reduce hyperinflation, and improve emptying of the lung and exercise performance. Due to these reasons, inhaled bronchodilators are the mainstay of the current management of all stages of COPD.
Bronchodilators Mode of Action Insights
-
Short-Acting Bronchodilators: This is expected to be the largest segment, owing to its ability to provide quick relief from sudden, unexpected attacks of breathlessness and can be used on a daily basis.
-
Long-Acting Bronchodilators: These type of bronchodilators helps in controlling the symptoms of asthma by opening the air passage. A major disadvantage of long-acting bronchodilators is that it increases the risk of asthma death. Hence, it should be used only as an added treatment for individuals or patients who use corticosteroids.
Bronchodilators Route of Administration Insights
-
Parenteral: This route of administration includes subcutaneous, intramuscular, and intravenous routes. The advantages of this route of administration include the complete bioavailability of the drug and rapid onset of action. However, there are certain disadvantages such as patient discomfort, the need for sterile conditions, and potential risks to health care practitioners from blood-borne pathogens.
Bronchodilators Regional Insights
-
Europe: The growing presence of the developed pharmaceutical industry and the significant demand for asthma-related therapeutics is driving the growth of the bronchodilators market in the Europe region. Additionally, rising cases of COPD and asthma is driving the market growth. An estimated 1.2 million people are living with diagnosed COPD, according to the British Lung Foundation. Moreover, around 2% of the whole population and 4.5% of all people aged over 40 live with diagnosed COPD in the UK.
Bronchodilators Market Top Key Players
- Novartis AG (Switzerland)
- Boehringer Ingelheim GmbH (Germany)
- Hoffmann LA-Roche AG (Switzerland)
- Teva Pharmaceutical (Israel)
Bronchodilators Market Trends
The increasing initiatives by public and private companies boost market growth. The growing number of clearances and product launches by key players in the market are likely to act as a promising factor for growth in the near future.
Bronchodilators Market Industry Developments
-
Q2 2024: GSK receives FDA approval for Trelegy Ellipta expanded indication in asthma GlaxoSmithKline announced that the U.S. FDA approved an expanded indication for its inhaled bronchodilator Trelegy Ellipta, allowing its use in a broader population of asthma patients.
-
Q1 2024: AstraZeneca’s Airsupra receives FDA approval for asthma maintenance AstraZeneca and Avillion announced that the FDA approved Airsupra, a combination bronchodilator, for the maintenance treatment of asthma in patients aged 18 years and older.
-
Q2 2024: Novartis launches Enerzair Breezhaler in Japan for COPD Novartis announced the commercial launch of Enerzair Breezhaler, a triple-combination bronchodilator, in Japan for the treatment of chronic obstructive pulmonary disease (COPD).
-
Q1 2024: Boehringer Ingelheim opens new respiratory drug manufacturing facility in Germany Boehringer Ingelheim inaugurated a new manufacturing facility dedicated to the production of inhaled bronchodilators and other respiratory medicines in Biberach, Germany.
-
Q2 2024: Pfizer announces partnership with Propeller Health to develop digital-connected bronchodilator inhalers Pfizer entered a strategic partnership with Propeller Health to co-develop digital inhalers for bronchodilator medications, aiming to improve adherence and outcomes in asthma and COPD patients.
-
Q2 2024: Sanofi receives EMA approval for new bronchodilator combination therapy for COPD Sanofi announced that the European Medicines Agency approved its new fixed-dose combination bronchodilator for the maintenance treatment of COPD in adults.
-
Q1 2025: Vectura Group secures contract to supply generic inhaled bronchodilator to NHS Vectura Group announced it has won a multi-year contract to supply its generic inhaled bronchodilator to the UK National Health Service, expanding access to affordable respiratory care.
-
Q2 2024: Teva launches generic version of ProAir HFA inhaler in the US Teva announced the US launch of its FDA-approved generic albuterol sulfate inhaler, expanding access to a widely used bronchodilator for asthma and COPD.
-
Q1 2024: AstraZeneca acquires respiratory biotech startup developing novel bronchodilator AstraZeneca completed the acquisition of a privately held biotech company focused on next-generation bronchodilator therapies for asthma and COPD.
-
Q2 2025: GlaxoSmithKline appoints new head of respiratory business unit GlaxoSmithKline announced the appointment of a new executive to lead its global respiratory business, which includes its portfolio of bronchodilator products.
-
Q1 2025: Novartis receives China NMPA approval for Ultibro Breezhaler in COPD Novartis announced that China's National Medical Products Administration approved Ultibro Breezhaler, a dual bronchodilator, for the treatment of COPD.
-
Q2 2024: Sanofi and Regeneron expand partnership to develop next-generation inhaled bronchodilators Sanofi and Regeneron announced an expanded collaboration to co-develop a pipeline of next-generation inhaled bronchodilators targeting severe asthma and COPD.
Report Attribute/Metric |
Details |
Market Size 2023 |
33.81 (USD Billion) |
Market Size 2024 |
35.57 (USD Billion) |
Market Size 2032 |
53.44 (USD Billion) |
Compound Annual Growth Rate (CAGR) |
5.78 % (2024 - 2032) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year |
2023 |
Market Forecast Period |
2024 - 2032 |
Historical Data |
2019 - 2023 |
  Geographies Covered |
  North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
  Key Vendors |
  GlaxoSmithKline (UK), Novartis AG (Switzerland), Merck & Co., Inc. (US), Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), Hoffmann LA-Roche AG (Switzerland), Teva Pharmaceutical (Israel), Pfizer Inc. (US) |
  Key Market Opportunities |
  Growing technological advancements and Growing funding by government organizations |
  Key Market Drivers |
Increase in prevalence of pulmonary disorders, The rise in disposable income and Increasing geriatric population |
Bronchodilators Market Highlights:
Frequently Asked Questions (FAQ):
The valuation of the global Bronchodilators market is estimated to reach USD 53.44 Billion during the forecast period.
The global Bronchodilators market is projected to grow at approximately 5.78% CAGR during the forecast period.
The rise in disposable income Increasing geriatric population
North America holds the largest share in the global Bronchodilators market, followed by Europe and the Asia Pacific, respectively.
Novartis AG (Switzerland), GlaxoSmithKline (UK), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Abbott Laboratories (US), AstraZeneca plc (UK), Teva Pharmaceutical (Israel), Hoffmann LA-Roche AG (Switzerland), and Pfizer Inc. (US), are some of the major players operating in the Bronchodilators market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report